Distinct models to assess the cost-effectiveness of EGFR-tyrosine kinase inhibitors for the treatment of metastatic non-small cell lung cancer in the context of the Brazilian Unified Health Care System
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.